HRP20030752A2 - Pyridazinone aldose reductase inhibitors - Google Patents

Pyridazinone aldose reductase inhibitors

Info

Publication number
HRP20030752A2
HRP20030752A2 HR20030752A HRP20030752A HRP20030752A2 HR P20030752 A2 HRP20030752 A2 HR P20030752A2 HR 20030752 A HR20030752 A HR 20030752A HR P20030752 A HRP20030752 A HR P20030752A HR P20030752 A2 HRP20030752 A2 HR P20030752A2
Authority
HR
Croatia
Prior art keywords
sulfonyl
pyridazin
alkyl
chloro
methylbenzofuran
Prior art date
Application number
HR20030752A
Other languages
English (en)
Croatian (hr)
Inventor
Lakshman Mylari Banavara
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HRP20030752A2 publication Critical patent/HRP20030752A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20030752A 2001-03-30 2003-09-17 Pyridazinone aldose reductase inhibitors HRP20030752A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28005101P 2001-03-30 2001-03-30
PCT/IB2002/000320 WO2002079198A1 (fr) 2001-03-30 2002-01-31 Inhibiteurs pyridazinone d'aldose réductase

Publications (1)

Publication Number Publication Date
HRP20030752A2 true HRP20030752A2 (en) 2005-06-30

Family

ID=23071435

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030752A HRP20030752A2 (en) 2001-03-30 2003-09-17 Pyridazinone aldose reductase inhibitors

Country Status (44)

Country Link
US (2) US6579879B2 (fr)
EP (3) EP1491540B1 (fr)
JP (1) JP2004528319A (fr)
KR (1) KR100586138B1 (fr)
CN (1) CN1215067C (fr)
AP (1) AP2002002461A0 (fr)
AR (1) AR035798A1 (fr)
AT (3) ATE286049T1 (fr)
AU (1) AU2002226634B2 (fr)
BG (1) BG108179A (fr)
BR (1) BR0208571A (fr)
CA (1) CA2442476A1 (fr)
CZ (1) CZ20032563A3 (fr)
DE (3) DE60216823T2 (fr)
DK (2) DK1373259T3 (fr)
EA (1) EA006023B1 (fr)
EC (1) ECSP034671A (fr)
EE (1) EE200300470A (fr)
ES (2) ES2274369T3 (fr)
GE (1) GEP20053675B (fr)
HK (1) HK1061678A1 (fr)
HR (1) HRP20030752A2 (fr)
HU (1) HUP0303644A3 (fr)
IL (1) IL156462A0 (fr)
IS (3) IS2205B (fr)
MA (1) MA27003A1 (fr)
MX (1) MXPA03008850A (fr)
MY (1) MY134304A (fr)
NO (1) NO20034345L (fr)
NZ (1) NZ528406A (fr)
OA (1) OA12453A (fr)
PA (1) PA8541801A1 (fr)
PE (1) PE20030007A1 (fr)
PL (1) PL365294A1 (fr)
PT (2) PT1373259E (fr)
SI (1) SI1373259T1 (fr)
SK (1) SK11852003A3 (fr)
TN (1) TNSN02037A1 (fr)
TW (1) TWI245762B (fr)
UA (1) UA73236C2 (fr)
UY (1) UY27237A1 (fr)
WO (1) WO2002079198A1 (fr)
YU (1) YU71403A (fr)
ZA (1) ZA200304671B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0934061T6 (en) 1996-07-24 2015-01-26 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
ATE297902T1 (de) * 2001-02-28 2005-07-15 Pfizer Prod Inc Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren
WO2002079198A1 (fr) * 2001-03-30 2002-10-10 Pfizer Products Inc. Inhibiteurs pyridazinone d'aldose réductase
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
TWI250980B (en) * 2002-01-09 2006-03-11 Pfizer Prod Inc Process and intermediates for pyridazinone antidiabetic agents
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20040092522A1 (en) * 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US6872833B2 (en) * 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
CA2568640C (fr) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Composition pharmaceutique contenant de l'irbesartan
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
EP1769088A2 (fr) * 2004-06-30 2007-04-04 Whitehead Institute For Biomedical Research Procedes pour analyse de site haut rendement au niveau du genome
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CA2636007A1 (fr) * 2006-01-13 2007-07-26 Wyeth 1h-indoles substitues par un groupe sulfonyle en tant que ligands pour les recepteurs de la 5-hydroxytryptamine
EP2041123B9 (fr) 2006-06-27 2013-01-02 Takeda Pharmaceutical Company Limited Composés cycliques condensés
EP2094643B1 (fr) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company Inhibiteurs d'amino cetp étendus
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
AU2010328186B2 (en) 2009-12-08 2014-12-18 Case Western Reserve University Compounds and methods of treating ocular disorders
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
KR20140091522A (ko) * 2011-09-15 2014-07-21 타이페이 메디컬 유니이버시티 심부전증 또는 신경 손상을 치료하기 위한 인돌릴 및 인돌리닐 하이드록사메이트의 용도
US9339542B2 (en) * 2013-04-16 2016-05-17 John L Couvaras Hypertension reducing composition
EP2986599A1 (fr) 2013-04-17 2016-02-24 Pfizer Inc. Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
EP3283074A4 (fr) * 2015-04-14 2018-12-05 Case Western Reserve University Compositions et procédés de modulation de l'activité de la déshydrogénase à chaîne courte
WO2017168174A1 (fr) 2016-04-02 2017-10-05 N4 Pharma Uk Limited Nouvelles formes pharmaceutiques du sildénafil
BR112018076244A2 (pt) 2016-06-21 2019-03-26 The Trustees Of Columbia University In The City Of New York inibidores da aldose redutase e métodos de uso destes
WO2018002673A1 (fr) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
WO2018058109A1 (fr) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions et méthodes pour le traitement de troubles métaboliques
EP3548035A4 (fr) 2016-11-30 2020-07-22 Case Western Reserve University Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
SG11202000730QA (en) 2017-07-28 2020-02-27 Applied Therapeutics Inc Compositions and methods for treating galactosemia
CA3125765A1 (fr) 2019-01-18 2020-07-23 Astrazeneca Ab Inhibiteurs de pcsk9 et leurs procedes d'utilisation
WO2020243423A1 (fr) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
KR20220030222A (ko) 2019-05-31 2022-03-10 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
WO2022120353A1 (fr) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
WO1992009594A1 (fr) * 1990-11-30 1992-06-11 Tsumura & Co. Derive de benzopyrone et inhibiteur de reductase d'aldose contenant ce derive en tant qu'ingredient actif
CA2107104A1 (fr) 1991-03-28 1992-09-29 Banavara L. Mylari Acides pyridazinoneacetiques utilises comme inhibiteurs de l'aldose reductase
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
HUP0003647A3 (en) * 1997-09-24 2002-12-28 Orion Corp Bisethers of 1-oxa, aza and thianaphthalen-2-ones, their use for producing medicaments, the medicaments and their intermediates
FR2822827B1 (fr) * 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
WO2002079198A1 (fr) * 2001-03-30 2002-10-10 Pfizer Products Inc. Inhibiteurs pyridazinone d'aldose réductase
IL157935A0 (en) * 2001-04-30 2004-03-28 Pfizer Prod Inc Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
TWI250980B (en) * 2002-01-09 2006-03-11 Pfizer Prod Inc Process and intermediates for pyridazinone antidiabetic agents

Also Published As

Publication number Publication date
BG108179A (en) 2004-09-30
IS8251A (is) 2006-01-23
MXPA03008850A (es) 2003-12-04
GEP20053675B (en) 2005-11-25
KR20030088484A (ko) 2003-11-19
TWI245762B (en) 2005-12-21
IS2205B (is) 2007-02-15
KR100586138B1 (ko) 2006-06-07
AU2002226634B2 (en) 2007-01-25
ZA200304671B (en) 2004-06-25
JP2004528319A (ja) 2004-09-16
DE60202452T2 (de) 2006-02-09
PE20030007A1 (es) 2003-01-28
HK1061678A1 (en) 2004-09-30
SI1373259T1 (en) 2005-04-30
DE60202452D1 (de) 2005-02-03
DE60216823T2 (de) 2007-10-04
DE60217930T2 (de) 2007-10-18
MA27003A1 (fr) 2004-12-20
TNSN02037A1 (fr) 2005-12-23
ECSP034671A (es) 2003-08-29
CN1215067C (zh) 2005-08-17
ATE352551T1 (de) 2007-02-15
NZ528406A (en) 2004-03-26
ATE348100T1 (de) 2007-01-15
CN1500087A (zh) 2004-05-26
IL156462A0 (en) 2004-01-04
IS8250A (is) 2006-01-23
DE60217930D1 (de) 2007-03-15
EP1491541A1 (fr) 2004-12-29
OA12453A (en) 2006-05-24
IS6845A (is) 2003-06-16
BR0208571A (pt) 2004-03-23
ATE286049T1 (de) 2005-01-15
HUP0303644A2 (hu) 2004-03-01
MY134304A (en) 2007-12-31
UA73236C2 (en) 2005-06-15
EA200300673A1 (ru) 2003-12-25
CA2442476A1 (fr) 2002-10-10
HUP0303644A3 (en) 2008-06-30
US6849629B2 (en) 2005-02-01
EA006023B1 (ru) 2005-08-25
EP1491540A1 (fr) 2004-12-29
DE60202452C5 (de) 2006-11-23
ES2274369T3 (es) 2007-05-16
EP1373259B1 (fr) 2004-12-29
EP1491540B1 (fr) 2006-12-13
DK1491540T3 (da) 2007-03-26
WO2002079198A1 (fr) 2002-10-10
NO20034345D0 (no) 2003-09-29
US20030162784A1 (en) 2003-08-28
DK1373259T3 (da) 2005-03-29
CZ20032563A3 (cs) 2004-05-12
EP1491541B1 (fr) 2007-01-24
EE200300470A (et) 2004-02-16
PT1373259E (pt) 2005-03-31
NO20034345L (no) 2003-09-29
PA8541801A1 (es) 2002-10-28
AR035798A1 (es) 2004-07-14
YU71403A (sh) 2006-05-25
ES2231681T3 (es) 2005-05-16
US6579879B2 (en) 2003-06-17
PT1491540E (pt) 2007-01-31
EP1373259A1 (fr) 2004-01-02
AP2002002461A0 (en) 2002-06-30
PL365294A1 (en) 2004-12-27
US20020143017A1 (en) 2002-10-03
UY27237A1 (es) 2002-12-31
DE60216823D1 (de) 2007-01-25
SK11852003A3 (sk) 2004-07-07

Similar Documents

Publication Publication Date Title
HRP20030752A2 (en) Pyridazinone aldose reductase inhibitors
AU2002226634A1 (en) Pyridazinone aldose reductase inhibitors
HRP20010716A2 (en) Aminopyrimidines as sorbitol dehydrogenase inhibitors
US6570013B2 (en) Salts of zopolrestat
KR20080087841A (ko) 무스카린 수용체의 조절제
EP2062898A2 (fr) Dérivés de cyclohéxane spirocycliques
TWI258478B (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
JP2001522374A (ja) ドパミンｄ３受容体モジュレーターとしての置換テトラヒドロイソキノリン類
US7572910B2 (en) Pyridazinone aldose reductase inhibitors
US20040198740A1 (en) Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2
AU2002236131A1 (en) Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
WO2002098429A1 (fr) Formes salines du zopolrestat, a savoir ethanolamine, diethanolamine ou triethanolamine

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODBC Application rejected